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Abstract 
Blocking the 2-C-methyl-D-erythrithol-4-phosphate pathway for isoprenoid synthesis offers 
new ways to inhibit Plasmodium spp. growth. Fosmidomycin ((3-(N-
hydroxyformamido)propyl)phosphonic acid); 1) and its acetyl homologue FR-900098 ((3-(N-
hydroxyacetamido)propyl)phosphonic acid); 2) potently inhibit 1-deoxy-D-xylulose-5-
phosphate reductoisomerase, a key enzyme in this pathway. Arylpropyl substituents were 
introduced at the β-position of the hydroxamate analogue of 2 to study changes in 
lipophilicity, as well as electronic and steric properties. The potency of several new 
compounds on the P. falciparum enzyme approaches that of 1 and 2. Activities against the 
enzyme and parasite correlate well, supporting the mode of action. Seven X-ray structures 
show that all of the new arylpropyl substituents displace a key tryptophan residue of the 
active-site flap, which had made favorable interactions with 1 and 2. Plasticity of the flap 
allows substituents to be accommodated in many ways; in most cases, the flap is largely 
disordered. Compounds can be separated into two classes based on whether the substituent on 
the aromatic ring is meta or para. Generally, meta-compounds are better inhibitors, and in 
both classes, smaller size is linked to better potency. 
 
  
Introduction 
Despite major efforts to reduce its incidence in the last decade, malaria remains one of the 
leading causes of death from a single infectious agent. The disease, caused mostly by 
Plasmodium falciparum, was responsible for an estimated 438 000 deaths in 2015.[ 1 ] 
Significant gains in recent years are being undermined by mounting resistance of the parasite 
to currently available drugs, so there is an urgent need for new chemical entities acting on 
new targets.     
After Jomaa and coworkers demonstrated that Plasmodia synthesize isoprenoids via the non-
mevalonate or 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway,[2] while humans obtain 
these essential molecules via the orthogonal mevalonate pathway,[ 3 ,4 ] blocking the MEP 
pathway became an attractive strategy to stem the proliferation of this and other pathogens.[5] 
1-Deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr; EC 1.1.1.267) catalyzes the first 
committed step in the MEP pathway, i.e. the transformation of 1-deoxy-D-xylulose 5-
phosphate (DOXP) to MEP.[6,7] The natural antibiotic fosmidomycin (1, Figure 1), a potent 
inhibitor of Dxr,[8,9] has been clinically evaluated for the treatment of malaria, alone and in 
combination therapy, but unfavorable pharmacokinetic properties and low intestinal 
absorption have prevented it from reaching the market.[10,11,12] The acetyl homologue of 
fosmidomycin, FR-900098 (2), has been reported to be twice as potent against P. falciparum 
in vitro, and against P. vinckei in a mouse malaria model.[2] Extensive medicinal chemistry 
efforts seeking new antimalarial agents have yielded various analogues of fosmidomycin, the 
subject of multiple reviews.[13,14,15] The phosphonate group and the metal-chelating reverse 
hydroxamate moiety are both required for Dxr inhibitory activity. Aryl substitutions at the -
position (with respect to the phosphonate), when attached to the inhibitor backbone via a 
linker of 3-4 carbon units, have yielded some of the most promising analogues to date. 
 
Figure 1: Conversion catalyzed by Dxr, and two inhibitors of this enzyme. 
Dxr enzymes contain a strictly conserved tryptophan residue within a flexible loop (flap) that 
undergoes an induced-fit conformational change upon fosmidomycin binding, closing over 
and interacting with the bound inhibitor. This flap is considered essential for Dxr’s catalytic 
activity.[16,17,18,19,20] Murkin and coworkers demonstrated a change in the rate-limiting step of 
the Mycobacterium tuberculosis Dxr-catalyzed reaction upon alteration of Trp203 in the flap, 
thereby establishing a functional link between this amino acid and chemical barrier 
crossing.[21] Inhibition and binding studies with fosmidomycin confirmed the importance of 
the flap, and the conserved tryptophan in particular, for ligand binding. Structural evaluation 
of a series of Dxr-bound compounds including 3 and 4 (Figure 2) showed that the indole 
group of Trp211 in the Escherichia coli enzyme (EcDxr) is displaced in order to 
accommodate the inhibitors’ pyridine/quinoline rings, which form π-π stacking or charge-
transfer interactions with the indole of the tryptophan side chain.[22]  
 
Figure 2. Relevant Dxr inhibitors (3-5) and target -substituted (6a-j) fosmidomycin 
analogues. 
Recently, we assessed the ability of Dxr to accommodate substituents in the -position of 
fosmidomycin analogues bearing a hydroxamate rather than the original reverse hydroxamate 
group.[23] We observed that direct introduction of aromatic rings at the -carbon (as in 5a) 
afforded moderate Dxr inhibitors. Exploration of different linkers between the β-carbon and a 
phenyl ring (5b-e) suggested that a 3-carbon linker (5d) was optimal for inhibition of EcDxr 
and M. tuberculosis Dxr, while both phenylpropyl (5d) and phenylbutyl (5e) substituents 
afforded potent P. falciparum Dxr (PfDxr) inhibitors. These results were rationalized by 
crystallographic studies of PfDxr in complex with 5d and 5e, which showed that the phenyl 
rings of these compounds displace the indole ring of the conserved Trp296 residue, and 
occupy its 'usual' position in both active-site metal-containing[16,18, 24 ] and metal-free 
structures.[17] This allows an intra-molecular interaction between the phenyl ring and the 
methyl group on the hydroxamic acid that is equivalent to the inter-molecular interactions 
observed in ternary complexes with 2.[18,24] Rearrangement of the residues of the flap results 
in favorable interactions between these phenyl rings and the tryptophan residue. Importantly, 
both analogues showed submicromolar schizontocidal activity against the P. falciparum K1 
strain, and essentially the same SAR was observed as for PfDxr inhibition.  
This follow-up study explored the influence of lipophilicity, electronic and steric properties in 
variants of the phenylpropyl side chain of 5d. We anticipated that analogues 6a-j would retain 
the capacity to occupy the aromatic 'hotspot', while their phenyl substituents might reinforce 
intra- or inter-molecular interactions. 
 
Results and discussion 
Synthesis 
 
Scheme 1. Reagents and conditions: i) but-3-yn-1-ol, PdCl2(PPh3), CuI, Et3N, 117 °C, 50%– 
98%; ii) H2, Pd/C, MeOH, 69–94%; iii) Dess-Martin periodinane, CH2Cl2; iv) 
Ph3P=CHCOOtert-Bu, toluene, 120 °C, 49%–67%; v) (BnO)2OPMe, n-BuLi, THF, -78 °C, 
43%–71%; vi) (a) TFA, CH2Cl2, 45 min, 0 °C to rt; (b) MeN(OBn)H, EDC, DMAP, CH2Cl2, 
18 h  rt, 44%–78%; vii) H2, Pd/C, MeOH, NaOHaq., 25 °C, 10-15 min, quantitative.   
The synthesis of 6a-j (Scheme 1) was achieved starting from commercially available aryl 
iodides 7a-j. Sonogashira coupling with but-3-yn-1-ol afforded the corresponding alkynols 
8a-j, which were readily converted to 9a-j upon catalytic hydrogenation. Dess-Martin 
oxidation to the corresponding aldehydes 10a-j and subsequent Wittig olefination afforded the 
,-unsaturated esters 11a-j, which served as electrophiles in a Michael reaction with 
dibenzyl methylphosphonate to yield the 1,4-addition adducts 12a-j. Hydrolysis of the tert-
butyl ester and EDC mediated coupling with O-benzyl-N-methyl-hydroxylamine gave 13a-j. 
Finally, removal of all benzyl protecting groups by catalytic hydrogenolysis afforded the 
desired analogues 6a-j.   
 
Evaluation of function 
The final compounds were tested for inhibition of recombinant EcDxr and PfDxr using a 
spectrophotometric assay monitoring the substrate-dependent oxidation of NADPH associated 
with the Dxr-catalyzed reaction (Table 1).[16,23, 25] 
Table 1. In vitro inhibition of recombinant Dxr enzymes, and as well as IC50 values against in 
vitro growth of the P. falciparum K1 strain. The IC50 values reported for EcDxr were 
calculated from a single curve, while those for PfDxr are based on triplicates  (the confidence 
interval is shown in parentheses). IC50 values on Plasmodium growth are the mean and 
standard deviation from three separate experiments. 
  IC50 (µM)[a] P. falciparum K1 
IC50 (μM)[b] Compound Structure EcDxr PfDxr 
1 
 
    nd[ac] 0.036  (0.032 
– 0.040) 
1.7 ± 0.9[26] 
2      0.03 (0.02-
0.05)[bd] 
0.045 (0.041-
0.049)[bd] 
0.4 ± 0.2[26] 
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 5d 
 
     0.84[23] (0.51-
1.40) 
 0.079 
(0.066-
0.093)[ce] 
2.7 ± 0.[df]
6a 
 
     1.04 (0.6-1.8) 0.175 (0.129-
0.237) 
1.4 ± 1.2 
6b 
 
     10.40 (2.8- 388.3) 0.05 (0.043-
0.049) 
10.9 ± 4.5 
6c 
 
     1.18 (0.4-3.3) 0.12 (0.096-
0.142) 
3.8 ± 2.5 
6d 
 
     0.97 (0.62 – 1.5) 0.15 (0.137-
0.154) 
7.8 ± 3.7 
6e 
 
     10.53 (2.4-46.2) 3.2 (2.83-
3.63) 
51.4 ± 21.8 
6f 
 
     2.00 (1.1-3.7) 0.067 (0.057-
0.078) 
5.7 ± 4.4 
6g 
 
     7.33 (0.9-59.6) 0.27 (0.248-
0.295) 
45.7 ± 21.3 
6h  
 
     13.91 (4.3-45.5) 0.28 (0.272-
0.298) 
49.3 ± 18.9 
6i 
 
     4.07 (1.5-11.2) 0.87 (0.780-
0.977) 
46.6 ± 15.4 
6j 
 
     nd[eg] 1.6 (1.16-
2.158) 
> 64 
 
[a] The IC50 values reported for EcDxr were calculated from a single curve, while those for 
PfDxr are based on triplicatesthree experiments;  (the confidence interval for each value is 
shown in parentheses). 
[b] IC50 values on Plasmodium growth are the mean and standard deviation from three 
separate experiments performed on different dates. 
[ac] nd = not determined; a value of 0.030 ± 0.008 was reported earlier.[27] 
[bd] Values of 0.051 and 0.018 were reported earlier for EcDxr and PfDxr, respectively.[28] 
[ce] A value of 0.117 ± 0.012 was reported earlier.[23] 
[df] A value of 0.43 ± 0.09 was reported earlier.[23] 
[eg] nd = not determined; 86% activity remained after the addition of 100 M 6j. 
 
None of the changes introduced in 6a-6j relative to 5d improve inhibition of EcDxr relative to 
5d, although 6a, 6c, 6d and 6f are essentially equipotent to 5d. Two changes improve 
inhibition of PfDxr relative to 5d (6b and 6f), while three others give similar IC50 values (6a, 
6c and 6d). The remaining changes are associated with weaker inhibition of PfDxr (6e, 6g-6j). 
Surprisingly, methyl-substitution of the aromatic ring at the meta-position (6b) increases 
PfDxr inhibition, while it unfavorably influences EcDxr inhibition (Figure S1). The same may 
be true for the meta-fluoro analogue 6f. 
None of the changes introduced in 6a-6j relative to 5d significantly improve the IC50 values 
regarding in vitro growth of the multidrug-resistant P. falciparum K1 strain (Table 1). 
However, improvement of IC50 for PfDxr is well correlated with improvements in the IC50 
against the parasite (Figure 3), indicating that Dxr is in fact the primary target of this series of 
compounds. Only inhibitors with IC50s better than approximately 0.3 M (pIC50 greater than 
6.5) had significant effects against the parasite at the highest concentration tested (64 M). 
 
 
Figure 3. Plot of IC50 against in vitro growth of the P. falciparum K1 strain versus pIC50 
against PfDxr activity, for the new compounds; 1 and 2 are shown for reference. Compounds 
marked with blue boxes represent those for which X-ray structures of complexes with PfDxr 
are reported in the present paper, while red/orange boxes represent structures reported 
elsewhere (ref. 23 and 18, respectively). 
 
Results against Trypanosoma brucei brucei Squib 427, T. cruzi Tulahuen LacZ (clone C4) 
and Leishmania infantum MHOM/MA(BE)/67 strains were also negative at the highest 
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concentrations tested  (64 M).[29] Since these parasites do not have Dxr, these were 
effectively control experiments. Cytotoxicity, as assessed against MRC-5SV2 (human lung 
fibroblast) cells, was also negligible for all compounds at this concentration. 
 
X-ray structures of PfDxr in complex with seven inhibitors 
The structures of PfDXR in complex with seven of the new -substituted inhibitors (6a-d, 6f, 
6g, 6h) are described in more detail in the Supporting Information. Although all of the new 
compounds were entered into crystallization trials, only inhibitors with IC50s better than ~0.5 
M (pIC50 greater than ~6.2) produced structures (Figures 3-5). The structures have been 
solved at resolutions in the range of 1.4-1.8 Å, and refined to crystallographic R-factors of 
~18% and free R-factors of 20-21%. Complete data collection and refinement statistics are 
given in Table S2. Each complex has been crystallized in space group P1, with similar unit 
cell constants. A dimer is found in the asymmetric unit, and a manganese ion and an inhibitor 
molecule are very clear in each active site (Figure 4A4a). The overall electron density is of 
good quality, and complete models of the enzyme are deposited at the PDB for residues 77-
486 in each chain. However, the electron density for even the main chain in some of the flap 
(residues 292-298) is sometimes poorly defined, see Table S3. Only in the complex with 6h, 
and in one molecule of 6d, is the main-chain electron density of each flap continuous at the 
r.m.s. value of the relevant map. The indole ring of Trp296 is poorly defined in six of the 14 
views of the active site. Although each compound was synthesized as a racemic mixture, the 
high resolution of the structures allowed us to identify the favored R-enantiomer in each 
complex, as observed in our earlier work.[23] The protein structures are highly conserved; a 
structural superposition of each chain onto the A chain of the 5d complex (PDB code 4Y67) 
produces r.m.s. values of 0.16-0.36 Å for 398-410 pairs of C atoms, when using a 1-Å C-
pair cut-off. The overlapping C-traces show separation into A and B chain clusters at the 
start of two helices in the cofactor-binding domain, probably as a result of differences in the 
crystal environment. Because the electron density in the flap is often poorly defined, the 
chains are not tightly clustered, but short regions before and after the flap show separate tight 
A- and B-chain clusters, again separated by ~0.5-1.0 Å, probably as a result of different 
crystal contacts. 
 
 Figure 4. X-ray structures of PfDxr in complex with inhibitors. The cartoon representation of 
the protein backbone is color-coded according to position in the sequence, going through the 
rainbow from red to blue. (Aa) Electron density for the inhibitor 6h and selected nearby 
atoms, contoured at the r.m.s. value of the σA-weighted (2m|Fo| − D|Fc|) electron-density 
map[30] (0.43 e/Å3) in light blue, as well as at 2.5 e/Å3 (gold) to show the higher electron 
density near the metal ion. (Bb) Superimposed structures of the meta-class compounds, 6b 
(light brown), 6d (orange), 6f (dark brown) and 6h (yellow), on 5d (silver gray). The well-
defined flap residue, Trp296, of 6h and 5d is seen to undergo a conformational change. (Cc) 
Superimposed structures of the para-class compounds, 6a (dark green), 6c (light green) and 
6g (cyan), on 5d (silver grey). Fluorine atoms are shown in magenta. (Dd) All the structures 
superimposed, using the same coloring scheme defined in panels B and C. 
There is no clear correlation between strength of inhibition and temperature factors or fit to 
electron density (Figure S2), which is perhaps to be expected given the variable 
conformations observed for the flap. 
Numerous crystallographic studies have shown that fosmidomycin analogues bind in the 
substrate/product-binding site of Dxr. The phosphonate group at one end is held firmly in 
place by multiple hydrogen-bonding interactions with protein and solvent, and the 
hydroxamic acid group at the other end is coordinated to the active-site metal ion. In ternary 
complexes with 1 and 2, a well-defined flap has been observed, with a number of highly 
conserved amino-acid side chains contributing to the binding site.[16,17,18,24] In particular, the 
indole ring of Trp296 (PfDxr numbering) packs against the backbone of the two compounds, 
and interacts with the methyl group of the acetyl derivative 2.[16,18,24] In the numerous 
structures with -aryl analogues, the flap is either disordered or has moved to allow the 
substituents to bind in a depression located between three ordered loops and a usually 
disordered flap. This depression is large enough to accommodate analogues with formyl, 
acetyl or phenyl substituents at the hydroxamate group, for example.[ 31 , 32 , 33 ] -aryl 
substituents, however, show at least two modes of binding.[23] For the 5a complex that lacks a 
linker, the phenyl group is positioned ‘under’ a well-defined flap, and the methyl group on the 
hydroxamic acid interacts with the indole ring of Trp296. For the 5d and 5e complexes, 
however, the linkers adopt boomerang-like conformations that, together with small changes in 
the fosmidomycin backbone, allow their respective phenyl groups to interact with the methyl 
group of their hydroxamic acid. In this strikingly different way of dealing with the 
substitution, the linker occupies the volume normally occupied by -aryl substitutions, while 
the phenyl ring is co-spatial with the indole ring of the flap tryptophan, as seen in ternary 
complexes.[16,17,18,24] The edge of the phenyl ring, in turn, interacts with the indole ring of 
Trp296 in the flap. All seven of the new -substituted complexes take on the same general 
structure seen in the 5d complex, but can be grouped into two sets depending on whether they 
represent meta- or para-substitutions to the phenyl ring. We have structures for 3 meta- (6b, 
6d, 6f) and 3 para- (6a, 6c, 6g) substitutions, as well as 6h, which we consider as a member 
of the meta-class.  
The members of the meta-class form a tight cluster of eight independent structures (including 
both subunits of the dimers), where the phenyl rings of the new compounds closely overlap 
that observed in the 5d complex (Figure 4B4b). Interactions of the phosphonate and 
hydroxamic acid groups in all complexes are essentially identical to those of the 5d 
complex,[23] as is the overall conformation of the fosmidomycin backbone. All members adopt 
the same pose, where the substituent is directed towards the indole ring of Trp296 in the 5d 
complex; none points in the other direction, towards His341. However, all inhibitors have an 
effect on the positioning of the indole ring, and on the quality of the electron density of the 
flap (Table S3). Unsurprisingly, the introduction of a naphthalene ring in 6h causes a large 
change in the conformation of Trp296, which is needed to prevent clashes (Figure 4B4b); the 
flap in this structure is well defined. Although there are no close contacts to the indole ring, 
only a few atoms of one edge of the naphthalene ring are solvent-exposed. The slightly 
smaller methoxyphenyl substituent in 6d causes a different movement of the tryptophan 
residue, needed to prevent close contacts between the indole ring and the methyl group. The 
flap is rather well defined in both chains, as is the density for the indole group, but the change 
in conformation results in a loss of the close contacts to the indole seen in the 5d complex. 
The methoxyphenyl group is approximately planar, and so occupies the same place as the 
corresponding portion of the naphthalene ring of 6h (Figure 4B4b). The methoxy group does 
not form any hydrogen-bonding interactions with the protein, and is shielded from the solvent 
by residues near 360. The introduction of the methyl and fluorine substituents in 6b and 6f, 
respectively, would result in close contacts to one edge of the indole, if the conformation seen 
in the 5d complex were maintained (three contacts are predicted, of 2.5 Å and ~3.1Å, in 6b 
and 6f, respectively). Instead, the flap moves, and the electron density in a three-residue 
segment of the flap  (residues 294-296) becomes poorly defined (Table S3); the indole ring is 
moderately clear in only one of the four active sites (that of the 6f A-chain). Compounds 6b 
and 6f show equal or better IC50s than 5d, however, while the other two meta-compounds 
have higher values (Figure 3 and Table 1). The lack of well-defined interactions between the 
best inhibitors and the indole ring of Trp296 suggests that the interactions with the indole that 
are observed in the 5d complex are not the most important determinants of the observed IC50s. 
However, it is striking that the larger the substituent, the higher the IC50 observed (Figure 
5A5a). We suggest that the most energetically favorable intra-molecular phenyl/methyl 
interactions are harder for inhibitors with larger substituents to attain in the complexes, 
because they occur in the context of enzyme-inhibitor interactions. 
 
 
Figure 5. Relationship between size of substituents and pIC50. The inhibitors and the residues 
of their respective flaps are colored on a common scale, going through the rainbow from the 
best pIC50 (red, using 1 as the endpoint) to the poorest (blue). (Aa) Complexes of the meta-
cluster are shown. It should be remembered that the 6b complex, in particular, has poor 
electron density for the indole of Trp296. (Bb) Complexes of the para-cluster are shown. 
Note that the 6g complex has no significant electron density in the flap, as well as weaker 
electron density in the 3-carbon linker of the inhibitor. 
 
The members of the para-group (6a, 6c, 6g) form a cluster of six similar structures that are 
distinct from those of the meta-group (Figure 4C4c). The interactions at the phosphonate and 
hydroxamic acid moieties are essentially identical in all complexes, as is the conformation of 
the fosmidomycin backbone. While their phenyl rings are closely co-planar with that of the 5d 
complex, the rings are not so tightly clustered and each is shifted to some degree within the 
binding site by virtue of the flexible 3-carbon linker. The smallest shift from 5d is associated 
with the smallest substitution, and so on: ~0.5 Å for 6a, ~0.7Å for 6c and ~1.0 Å for 6g. This 
results from steric constraints near Met360/Pro363 that “push” the larger substituents away. 
Small differences in the torsion angles give the effect of splaying the linker, while sliding the 
ring in the plane of the phenyl ring seen in 5d (Figure 4C4c). The important intra-ligand ring-
methyl group interactions are, therefore, maintained in all complexes, but with variations 
(Figure 4D4d). Again, the electron density in each complex is poorly defined in regions of the 
flap; the indole ring of Trp296 is well defined in only three active sites, see Table S3. In these 
three complexes, Trp296 is similar to the 5d complex, and the indole ring helps to shield the 
edge of the phenyl ring of the inhibitor. However, the tryptophan is not forced out of the 
active site, as was observed for the largest meta-group compounds. Two of the fluorine atoms 
in 6g interact with a water molecule that is highly conserved in the various structures 
(although slightly displaced in the 6a complex), while the oxygen atom in the methoxy-
substituent of 6c accepts a hydrogen bond from the main-chain amide nitrogen of residue 359. 
In general, the larger the para-group substituent, the poorer the IC50 (Figure 5B5b). This is 
probably due to the translation of the relevant phenyl group from its energetically-preferred 
position in the 5d complex, although this is compensated for in part by interactions of 6g and 
6c with structurally-conserved polar atoms. Overall, the para-substituted ligands are poorer 
inhibitors than their meta-equivalents (placing 6i in the para-group, as the para-equivalent of 
6h). 
 
Conclusions 
 In the present work, we continued our systematic study of β-substituted hydroxamate 
analogues of fosmidomycin. Specifically, we explored the effects of changes in lipophilicity, 
electronic and steric properties versus the phenylpropyl side chain of the earlier compound 
5d. Several of the new compounds exhibit potency on PfDxr that approaches that of 1 and 2. 
There is a good correlation between activity against the enzyme, and activity against the 
parasite, indicating that their primary mode of biological action is in fact via PfDxr. Seven 
new X-ray structures show that all of the new arylpropyl substituents displace the key 
tryptophan residue of the active-site flap, which had made favorable interactions with the 
reverse hydroxamate group of 1 and its acetyl homologue 2. The plasticity of the flap allows 
the various compounds to be accommodated in many ways, and indeed in most cases, the flap 
is largely disordered. However, the structures results can be separated into two classesgroups, 
based on whether the substituent on the aromatic ring is meta or para. Generally, meta-
compounds are better inhibitors, and in both classes smaller substituents are associated with 
better potency. The large lipophilic biphenyl and naphthyl substituents provided poor 
inhibitors of Dxr, which was not compensated for by any advantages such compounds might 
provide regarding entry into the parasite cell and apicoplast, or other factors. Future directions 
should include tests of additional small substituents, particularly ones that could make good 
interactions with one of the favored conformations of the enzyme. However, it remains to be 
seen whether intestinal absorption, pharmacokinetic properties or other properties are 
improved for any of the -arylpropyl analogues. The strength of the present study is that it 
provides multiple viable compounds for additional biological work, increasing the chances of 
ultimate success in the effort to develop useful drugs of the fosmidomycin class. 
 
Experimental section  
General 
All reactions described were performed under an argon atmosphere and at ambient 
temperature unless stated otherwise. All reagents and solvents were purchased from Sigma-
Aldrich (Diegem, Belgium), Acros Organics (Geel Belgium) or TCI Europe (Zwijndrecht, 
Belgium) and used as received (except THF). Tetrahydrofuran was dried over 
sodium/benzophenone. NMR solvents were purchased from Eurisotop (Saint-Aubin, France). 
Reactions were monitored by TLC analysis using TLC aluminium sheets (Macherey-Nagel, 
Alugram Sil G/UV254). Detection was observed by spraying with a solution of 
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(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in H2SO4 (10%) followed 
by charring or immersion in an aqueous solution of KMnO7 (20 g/L) and K2CO3 (10 g/L) or 
an ethanolic solution of ninhydrin (2 g/L) and acetic acid (1% v/v) followed by charring. 
Silica gel column chromatography was performed manually using Grace Davisil 60Å silica 
gel (40-63 μm) or automated using a Grace Reveleris X2 system and the corresponding flash 
cartridges. High resolution spectra were recorded with a Waters LCT Premier XE Mass 
spectrometer. 1H- and 13C-NMR spectra were recorded with a Varian Mercury-300BB 
(300/75 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane 
(1H NMR) or the NMR solvent (13C NMR) as an internal standard. In 31P NMR, signals are 
referenced to the CDCl3 or D2O lock resonance frequency according to IUPAC referencing, 
with H3PO4 set to 0.00 ppm. Coupling constants are given in Hz. Preparative HPLC 
purifications were carried out using a Laprep preparative HPLC system equipped with an 
Xbridge Prep C18 column (19×250 mm, 5 micron) using a water/acetonitrile/formic acid 
gradient solvent system. All synthesized compounds were ≥95% pure as verified by LCMS. 
General Procedure I: Sonogashira coupling towards aralkynols 8a–j    
To a solution of the aryl iodides (7a–j) in degassed triethylamine, was added PdCl2(PPh3)2, 
CuI and but-3-yn-1-ol. The reaction mixture was refluxed at 117 °C for 3 h after which, it was 
cooled and concentrated in vacuo. Column chromatography using a Hex/EtOAc solvent 
system  afforded compounds 8a–j.    
General Procedure II: Triple bond reduction  
To a solution of the alkynes 8a–j in MeOH, was added 10 % of Pd/C under a nitrogen 
atmosphere. Molecular hydrogen (H2) was bubbled through the mixture for 30 minutes 
followed by filtration through a Whatman filter paper path. In vacuo concentration yielded 
compounds 9a–j which were used for the next step without further purification.  
General Procedure III: Dess-Martin oxidation and concomitant Wittig olefination 
A solution of the starting materials (9a–j) in CH2Cl2 and a nitrogen atmosphere was cooled to 
0 °C. Dess-Martin periodinane (2.0 equiv) was added and the mixture allowed to attain RT. 
After stirring for 3 h, TLC analysis showed a completed reaction. The reaction mixture was 
washed once with a 5:1 mixture of NaHCO3 (sat. aq.) and Na2S2O3 (aq. 2.0 M), and the water 
layer extracted three times with diethyl ether. The combined organic layer was washed 
successively with a 0.1 M solution of HCl and brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo to obtain the corresponding aldehydes (10a–j) which was used without 
further purification. The aldehyde was dissolved in toluene under nitrogen atmosphere and 
tert-butyl (triphenylphosphoranylidene)acetate (3 equiv) was added. An overnight reflux at 
120 °C, was followed by cooling and in vacuo concentration. Sorption of the crude on celite 
and silica gel chromatography gave access to the tert-butyl esters 11a–j.  
General procedure IV: Michael addition of methylphosphonatediesters to α,β-
unsaturated tert-butyl esters.  
To a solution of dibenzylmethyl phosphonate (2 eq.) in THF and under a nitrogen atmosphere 
was added n-BuLi (2 eq.) at -78 °C. After 30 minutes, a solution of the ester was added to the 
reaction mixture dropwise. Three hours later, the reaction showed to be complete by TLC and 
was quenched with NH4Cl (sat. aq.). The water layer was extracted three times with EtOAc. 
Organic fractions were pooled, washed once with brine and dried over anhydrous Na2SO4. 
Column chromatography (EtOAc/Hex system) afforded the adducts 12a–j.  
General procedure V: Acidic cleavage of the tert-butyl ester and protected hydroxamate 
formation   
A 0.1 M solution of the starting materials (12a–j) in CH2Cl2/TFA (80:20), at 0 °C, was stirred 
for two hours, after which an excess of toluene was added to the reaction mixture and 
concentrated in vacuo. The crude acid was redissolved in CH2Cl2 (0.1 M), followed by 
addition of EDC (1.2 equiv), DMAP (1.2 equiv) and triethylamine (2.0 equiv).  O-Benzyl-N-
methylhydroxylamine TFA salt (1.2 equiv) was added as a 0.2 M solution in CH2Cl2, and the 
mixture stirred overnight at RT. The reaction was subsequently quenched with sat. aq. 
NaHCO3, extracted three times with CH2Cl2, washed with brine and dried over Na2SO4. 
Column chromatography (CH2Cl2/MeOH system) produced the protected hydroxamic acids 
yielded compounds 13a–j.    
General procedure VI: Catalytic hydrogenolysis of benzyl protective groups 
The benzyl protected compounds 13a–j (100-130 mg) was dissolved in MeOH (10 ml) under 
inert atmosphere and 10 % of Pd/C was added. The resulting mixture was then stirred under 
hydrogen atmosphere while monitoring the progress by mass spectroscopy. At completion 
(about 10 minutes), the reaction mixture was filtered and neutralized with NaOH (1 equiv). 
The reaction mixture was then concentrated in vacuo, re-dissolved in a 1:1 (v/v) mixture of 
water and tert-butanol, frozen and lyophilized to afford the desired targets compounds 6a–j as 
monosodium phosphonic acid salts in quantitative yield.  
 
Tert-butyl (E)-6-(p-tolyl)hex-2-enoate (11a): Prepared according to general procedure III. 
Purification 1:1 toluene/hexane v/v; yield 59%.1H NMR (300 MHz, CDCl3) δH ppm 1.47 (br. 
s, 9H, t-Bu), 1.75 (app. quint. J = 8.0 Hz, 2H, -CH2-), 2.12-2.23 (m, 2H, -CH2-), 2.30 (s, 3H, 
Ph-CH3), 2.58 (t, J = 7.5 Hz, 2H, -CH2-), 5.74 (dt, J = 1.5 Hz, 15.6 Hz, 1H, -CH=CHCO), 
6.87 (dt J = 7.1 Hz, 15.6 Hz, 1H, -CH=CHCO), 7.00-7.16 (m, 4H, Ar-H). 13C-NMR (75 MHz, 
CDCl3) δC ppm 20.9, 28.1, 29.7, 31.4, 34.7, 79.9, 123.2, 128.2, 128.9, 135.2, 138.6, 147.5, 
170.0. HRMS (ESI): calculated for C17H25O2 [(M+H)+], 261.1849; found 261.1856.   
Tert-butyl (E)-6-(m-tolyl)hex-2-enoate (11b): Prepared according to general procedure III. 
Purification 1:1 toluene/hexane v/v; yield 51%. 1H NMR (300 MHz, CDCl3) δH ppm 1.44 (br. 
s, 9H, t-Bu), 1.76 (app. quint. J = 7.7 Hz, 2H, -CH2-), 2.14-2.24 (m, 2H, -CH2-), 2.32 (s, 3H, 
Ph-CH3), 2.59 (t, J = 7.7 Hz, 2H, -CH2-), 5.75 (dt, J = 1.6 Hz, 15.6 Hz, 1H, -CH=CHCO), 
6.87 (dt J = 6.9 Hz, 15.5 Hz, 1H, -CH=CHCO), 6.93-7.02 (m, 3H Ar-H), 7.12-7.20 (m, 1H, 
Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 21.3 , 28.1, 29.7, 31.5, 35.2, 80.0, 123.3, 125.4, 
126.6, 128.2, 129.2, 137.8, 141.7, 147.5, 166.0. HRMS (ESI): calculated for C17H25O2 
[(M+H)+], 261.1849; found 261.1852.  
Tert-butyl (E)-6-(4-methoxyphenyl)hex-2-enoate (11c): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 64%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.47 (br. s, 9H, t-Bu), 1.73 (app. quint. J = 7.7 Hz, 2H, -CH2-), 2.12-2.23 (m, 2H, -CH2-), 
2.32 (s, 3H, Ph-CH3), 2.57 (t, J = 7.4 Hz, 2H, -CH2-), 3.76 (s, 3H, PhOCH3), 5.74 (dt, J = 1.7 
Hz, 15.7 Hz, 1H, -CH=CHCO), 6.82 (dt J = 6.4 Hz, 15.7 Hz, 1H, -CH=CHCO), 7.26-7.42 (m, 
4H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 29.8, 31.3, 34.2, 55.1, 78.3, 113.7, 
123.2, 129.2, 133.7, 147.5, 157.7, 166.0. HRMS (ESI): calculated for C17H25O3 [(M+H)+], 
277.1798; found 277.1790.  
Tert-butyl (E)-6-(3-methoxyphenyl)hex-2-enoate (11d): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 65%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.46 (br. s, 9H, t-Bu), 1.76 (app. quint. J = 7.6 Hz, 2H, -CH2-), 2.16-2.24 (m, 2H, -CH2-), 
2.57 (t, J = 7.6 Hz, 2H, -CH2-), 3.72 (s, 3H, PhOCH3),  5.73 (dt, J = 1.6 Hz, 15.7 Hz, 1H, -
CH=CHCO), 6.87 (dt J = 6.9 Hz, 15.7 Hz, 1H, -CH=CHCO), 6.92-7.04 (m, 3H Ar-H), 7.12-
7.21 (m, 1H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 27.9 , 28.1, 29.4, 31.5, 35.8, 80.0, 
123.3, 125.4, 126.6, 128.2, 129.2, 137.8, 141.7, 146.8, 165.4. HRMS (ESI): calculated for 
C17H25O3 [(M+H)+], 277.1798; found 277.1799.  
Tert-butyl (E)-6-(4-fluorophenyl)hex-2-enoate (11e): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 53%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.47 (br. s, 9H, t-Bu), 1.66-1.82 (app. quint, J = 7.6 Hz, 2H, -CH2-), 2.19 (m, 2H, -CH2-), 
2.60 (t, J = 7.4 Hz, 2H, -CH2-), 5.75 (dt, J = 1.7 Hz, 15.80 Hz, 1H, -CH=CHCO), 6.80-7.00 
(m, 3H, -CH=CHCO, Ar-H), 7.06-7.15 (m, 2H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 
28.1, 29.8, 31.3, 34.4, 80.0, 115.0 (d, 2JC-F = 20.9 Hz), 123.4, 129.7 (d, 3JC-F = 8.8 Hz), 137.3 
(d, 4JC-F = 3.6 Hz), 147.2, 161.3 (d, 1JC-F = 242.9 Hz), 166.0. HRMS (ESI): calculated for 
C16H22FO2 [(M+H)+], 265.1598; found 265.1597. 
Tert-butyl (E)-6-(3-fluorophenyl)hex-2-enoate (11f): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 49%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.48 (br. s, 9H, t-Bu), 1.78 (app. quint. J = 8.0 Hz, 2H, -CH2-), 2.15-2.25 (m, 2H, -CH2-), 
2.63 (t, J = 7.7 Hz, 2H, -CH2-), 5.75 (dt, J = 1.7 Hz, 15.6 Hz, 1H, -CH=CHCO), 6.79-6.97 (m, 
4H, -CH=CHCO, Ar-H), 7.18-7.27 (m, 1H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 
29.4, 31.3, 34.9 (d, 4JC-F = 1.8 Hz), 80.1, 112.7, 115.2 (d, 2JC-F = 21.1 Hz), 123.5, 124.0 (d, 4JC-
F = 2.8 Hz), 129.7 (d, 3JC-F = 8.2 Hz), 144.3 (d, 3JC-F = 7.1 Hz), 147.1, 162.8 (d, 2JC-F = 245.5 
Hz), 166.0. HRMS (ESI): calculated for C16H22FO2 [(M+H)+], 265.1598; found 265.1599.  
Tert-butyl (E)-6-(4-(trifluoromethyl)phenyl)hex-2-enoate (11g): Prepared according to 
general procedure III. Purification 1:1 toluene/hexane v/v; yield 60%. 1H NMR (300 MHz, 
CDCl3) δH ppm 1.48 (br. s, 9H, t-Bu), 1.80 (app. quint. J = 7.5 Hz, 2H, -CH2-), 2.21 (m, 2H, -
CH2-), 2.69 (t, J = 7.8 Hz, -CH2-), 5.76 (dt, J = 1.8 Hz, 15.6 Hz, 1H, -CH=CHCO), 6.86 (dt, J 
= 6.8 Hz, 15.6 Hz, 1H, -CH=CHCO), 7.28 (d, J = 9.0 Hz, 2H, Ar-H), 7.54 (d, J = 8.5 Hz, 2H, 
Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 29.4, 31.3, 35.0, 80.1, 123.6, 124.3 (quart., 
1JC-F = 271.9 Hz), 125.3 (quart., 3JC-F = 7.2 Hz), 128.3 (quart., 2JC-F = 32.5 Hz), 128.7, 145.9, 
146.9, 165.9. HRMS (ESI): calculated for C17H22F3O2 [(M+H)+], 315.1566; found 315.1570.  
Tert-butyl (E)-6-(naphthalen-1-yl)hex-2-enoate (11h): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 67%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.47 (br. s, 9H, t-Bu), 1.90 (app. quint. J = 7.6 Hz, 2H, -CH2-), 2.21-2.31 (m, 2H, -CH2-), 
3.08 (t, J = 7.6 Hz, -CH2-), 5.78 (dt, J = 1.5 Hz, 15.6 Hz, 1H, -CH=CHCO), 6.91 (dt, J = 6.9 
Hz, 15.6 Hz, 1H, -CH=CHCO), 7.26-7.53 (m, 4H, Ar-H), 7.70 (d, J = 8.4 Hz, 1H, Ar-H), 
7.80-8.00 (m, 2H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 28.9, 31.8, 32.4, 80.0, 
123.4, 123.6, 125.4, 125.5, 125.7, 126.0, 126.7, 128.7, 131.7, 133.9, 137.8, 147.3, 166.0. 
HRMS (ESI): calculated for C20H25O2 [(M+H)+], 297.1849, found 297.1854. 
Tert-butyl (E)-6-(naphthalen-2-yl)hex-2-enoate (11i): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 67%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.48 (br. s, 9H, t-Bu), 1.84 (app. quint. J = 8.1 Hz, 2H, -CH2-), 2.21 (m, 2H, -CH2-), 2.77 
(t, J = 7.7 Hz, -CH2-), 5.76 (dt, J = 1.6 Hz, 15.2 Hz, 1H, -CH=CHCO), 6.89 (dt, J = 7.3 Hz, 
15.8 Hz, 1H, -CH=CHCO), 7.29 (dd, J = 1.8 Hz, 8.4 Hz, 1H, Ar-H), 7.36-7.47 (m, 2H, Ar-H), 
7.58 (s, 1H, Ar-H), 7.71-7.81 (m, 2H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 29.5, 
31.4, 35.3, 80.0, 123.3, 125.1, 125.8, 126.4, 127.1, 127.3, 127.5, 127.9, 132.0, 133.5, 139.2, 
147.4, 166.0. HRMS (ESI): calculated for C20H25O2 [(M+H)+], 297.1849; found 297.1852. 
Tert-butyl (E)-6-([1,1'-biphenyl]-4-yl)hex-2-enoate (11j): Prepared according to general 
procedure III. Purification 1:1 toluene/hexane v/v; yield 61%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.48 (br. s, 9H, t-Bu), 1.84 (app. quint. J = 7.5 Hz, 2H, -CH2-), 2.21-2.35 (m, 2H, -CH2-), 
2.65 (t, J = 7.8 Hz, -CH2-), 5.75 (dt, J = 1.7 Hz, 15.7 Hz, 1H, -CH=CHCO), 6.90 (dt, J = 6.8 
Hz, 15.7 Hz, 1H, -CH=CHCO), 7.22 (d, J = 8.5 Hz, 2H, Ar-H),  7.27-7.67 (m, 7H, Ar-H). 
13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 29.6, 31.4, 34.8, 80.0, 123.4, 126.9, 127.0, 127.1, 
128.7, 128.8, 138.8, 140.8, 141.0, 147.4, 166.0. HRMS (ESI): calculated for C22H27O2 
[(M+H)+], 323.2006, mass not found. 
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(p-tolyl)hexanoate (12a): Prepared 
according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 54%. 1H 
NMR (300 MHz, CDCl3) δH ppm 1.38 (br. s, 9H, t-Bu), 1.42-1.62 (m, 4H, -CH2-), 1.76-1.95 
(m, 2H, -CH2-), 2.19-2.32 (m, 5H, Ph-CH3, -CH2-), 2.35-2.54 (m, 3H, -CH2-, -CH-), 4.87-
5.08 (m, 4H, -CH2-Ph), 6.97-7.08 (m, 4H, Ar-H), 7.28-7.35 (m, 10H, Ar-H). 13C-NMR (75 
MHz, CDCl3) δC ppm 21.2, 28.3, 28.7, 30.1 (d, 1JC-P = 138.6 Hz), 30.6 (d, 2JC-P = 4.1 Hz), 
31.1, 34.5 (d, 3JC-P = 10.1 Hz), 35.6, 40.5 (d, 3JC-P = 9.3 Hz), 66.9 (d, 2JC-P = 6.6 Hz), 67.0 (d, 
2JC-P = 6.6 Hz), 80.2, 127.9, 127.9, 128.2, 128.3, 128.5, 128.9, 135.0, 136.4 (d, 3JC-P = 6.2 Hz), 
136.4 (d, 3JC-P = 6.0 Hz), 139.1, 171.6. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.29. 
HRMS (ESI): calculated for C32H42O5P [(M+H)+], 537.2764; found 537.2778. 
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(m-tolyl)hexanoate (12b): Prepared 
according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 45%. 1H 
NMR (300 MHz, CDCl3) δH ppm 1.39 (br. s, 9H, t-Bu), 1.42-1.63 (m, 4H, -CH2-), 1.78-1.98 
(m, 2H, -CH2-), 2.17-2.34 (m, 5H, Ph-CH3, -CH2-), 2.35-2.54 (m, 3H, -CH-, -CH2-), 4.88-
5.08 (m, 4H, -CH2-Ph), 6.88-7.00 (m, 3H, Ar-H), 7.14 (t, J = 7.7 Hz, 1H, Ar-H), 7.28-7.37 
(m, 10H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 21.6, 28.3, 28.6, 30.1 (d, 1JC-P = 138.6 
Hz), 30.6 (d, 2JC-P = 3.9 Hz), 34.6 (d, 3JC-P = 10.3 Hz), 36.1, 40.5 (d, 3JC-P = 10.3 Hz), 67.3 (d, 
2JC-P = 6.2 Hz), 80.6, 125.6, 126.7, 128.2, 128.4, 128.6, 128.8, 128.4, 136.7 (d, 3JC-P = 7.1 Hz), 
138.0, 142.5, 171.9. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.29. HRMS (ESI): calculated 
for C32H42O5P [(M+H)+], 537.2764; found 537.2786. 
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(4-methoxyphenyl)hexanoate (12c): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
53%. 1H NMR (300 MHz, CDCl3) δH ppm 1.39 (br. s, 9H, t-Bu), 1.43-1.97 (m, 6H, -CH2-), 
2.17-2.52 (m, 5H, -CH2-, -CH-), 3.77 (s, 3H, PhOCH3), 4.88-5.10 (m, 4H, -CH2-Ph), 6.79 (d, 
J = 9.1 Hz, 2H, Ar-H), 7.02 (d, J = 9.1 Hz, 2H, Ar-H), 7.26-7.44 (m, 10H, Ar-H). 13C-NMR 
(75 MHz, CDCl3) δC ppm 28.0, 28.5, 29.8 (d, 1JC-P = 138.5 Hz), 30.3 (d, 2JC-P = 3.9 Hz), 34.2 
(d, 3JC-P = 10.7 Hz), 34.9, 40.2 (d, 3JC-P = 9.9 Hz), 55.2, 67.0 (d, 2JC-P = 6.1 Hz), 67.0 (d, 2JC-P = 
6.7 Hz), 80.3, 113.7, 127.9, 128.3, 128.5, 129.2, 134.3, 136.4 (d, 3JC-P = 5.3 Hz), 136.4 (d, 3JC-
P = 5.9 Hz), 157.7, 171.6. 31P-NMR (121.5 MHz, CDCl3): 32.18. HRMS (ESI): calculated for 
C32H42O6P [(M+H)+], 553.2714; found 553.2717.            
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(3-methoxyphenyl)hexanoate (12d): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
47%. 1H NMR (300 MHz, CDCl3) δH ppm 1.39 (br. s, 9H, t-Bu), 1.42-1.63 (m, 4H, -CH2-), 
1.76-1.93 (m, 2H, -CH2-), 2.19-2.54 (m, 5H, -CH2-, -CH-), 3.76 (s, 3H, PhOCH3), 4.87-5.08 
(m, 4H, –CH2-Ph), 6.65-6.74 (m, 3H, Ar-H), 7.16 (t, J = 8.1 Hz, 1H, Ar-H), 7.28-7.36 (m, 
10H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.3, 28.5, 30.2 (d, 1JC-P = 139.8 Hz), 30.6 
(d, 2JC-P = 4.1 Hz), 34.5 (d, 3JC-P = 11.0 Hz), 36.1, 40.4 (d, 3JC-P = 9.4 Hz), 55.3, 67.2 (d, 2JC-P = 
4.1 Hz), 67.3 (d, 2JC-P = 4.3 Hz), 80.6, 111.2, 114.4, 121.0, 128.2, 128.6, 128.8, 129.5, 136.6 
(d, 3JC-P = 1.5 Hz), 136.7 (d, 3JC-P = 6.0 Hz), 136.7 (d, 3JC-P = 6.0 Hz),  144.1, 159.8, 171.9. 
31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.24. HRMS (ESI): calculated for C32H42O6P 
[(M+H)+], 553.2714; found 553.2717. 
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(4-fluorophenyl)hexanoate (12e): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
43%. 1H NMR (300 MHz, CDCl3) δH ppm 1.38 (br. s, 9H, t-Bu), 1.42-1.61 (m, 4H, -CH2-), 
1.76-1.96 (m, 2H, -CH2-), 2.16-2.34 (m, 2H, -CH2-), 2.18-2.52 (m, 3H, -CH2-, -CH-), 4.89-
5.08 (m, 4H, -CH2-Ph), 6.78-6.96 (m, 2H, Ar-H), 7.03 (m, 2H, Ar-H), 7.28-7.37 (m, 10H, Ar-
H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.0, 28.4, 29.9 (d, 1JC-P = 138.9 Hz), 30.3 (d, 2JC-P = 
3.9 Hz), 34.1 (d, 3JC-P = 10.2 Hz), 34.9, 40.2, (d, 3JC-P = 10.2 Hz), 67.0 (m), 80.3, 114.9 (d, 2JC-
F = 20.4 Hz), 127.9, 128.3, 128.5, 129.6 (d, 3JC-F = 7.7 Hz), 136.4 (d, 3JC-P = 6.3 Hz), 137.8 (d, 
4JC-F = 3.3 Hz), 161.1 (d, 1JC-F = 243.0 Hz), 171.6. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 
33.00. HRMS (ESI): calculated for C31H39FO5P [(M+H)+], 541.2514; found 541.2519. 
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(3-fluorophenyl)hexanoate (12f): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
47%. 1H NMR (300 MHz, CDCl3) δH ppm 1.33-1.40 (br. s, 9H, t-Bu), 1.41-1.61 (m, 4H, -
CH2-), 1.72-1.97 (m, 2H, -CH2-), 2.18-2.33 (2H, m, -CH2-), 2.36-2.55 (m, 3H, -CH2-, -CH-), 
4.89-5.08 (m, 4H, CH2-Ph), 6.76-6.90 (m, 3H, Ar-H), 7.19 (td, 1H, J = 6.08 Hz, 13.96 Hz, Ar-
H), 7.29-7.39 (m, 10H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.2, 28.3, 30.2 (d, 1JC-P = 
139.9 Hz), 30.5 (d, 2JC-P = 4.9 Hz), 34.4 (d, 3JC-P = 10.8 Hz), 35.7, 40.5 (d, 3JC-P = 9.8 Hz), 
66.9 (d, 2JC-P = 6.6 Hz), 67.0 (d, 2JC-P = 6.4 Hz), 80.6, 112.8 (d, 2JC-F = 21.0 Hz), 115.4 (d, 2JC-F 
= 20.7 Hz), 124.2 (d, 4JC-F = 3.1 Hz), 128.2, 128.6, 128.8, 129.9 (d, 3JC-F = 8.3 Hz), 136.3 (d, 
3JC-P = 6.3 Hz), 136.4 (d, 3JC-P = 6.4 Hz), 145.1(d, 3JC-F = 7.3 Hz), 162.8 (d, 1JC-F = 246.5 Hz), 
171.8 31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.16. HRMS (ESI): calculated for 
C31H39FO5P [(M+H)+], 541.2514; found 541.2515. 
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(4-
(trifluoromethyl)phenyl)hexanoate (12g): Prepared according to general procedure IV. 
Purification 2:1 hexane/ethyl acetate v/v; yield 62%. 1H NMR (300 MHz, CDCl3) δH ppm 
1.37 (br. s, 9H, t-Bu), 1.41-1.64 (m, 4H, -CH2-), 1.72-1.96 (m, 2H, -CH2-), 2.18-2.61 (m, 5H, 
-CH2-, -CH-), 4.90-5.09 (m, 4H, -CH2-Ph), 7.19 (d, J = 8.0 Hz, 2H, Ar-H), 7.28-7.36 (m, 
10H, Ar-H), 7.49 (d, J = 8.0 Hz, 2H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.3, 28.4, 
30.2 (d, 1JC-P = 138.2 Hz), 30.6 (d, 2JC-P = 5.4 Hz), 34.4 (d, 3JC-P = 10.8 Hz), 35.9, 40.6 (d, 3JC-P 
= 9.2 Hz), 67.4 (d, 2JC-P = 6.7 Hz), 67.5 (d, 2JC-P = 6.6 Hz), 80.8, 124.6 (quart., 1JC-F= 271.5 
Hz), 125.5 (quart., 3JC-F = 3.8 Hz), 128.3, 128.5 (quart., 2JC-F = 27.1 Hz), 128.7, 128.9, 129.0, 
136.7 (d, 3JC-P = 6.0 Hz), 146.7, 171.9. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 31.86 
HRMS (ESI): calculated for C32H39F3O5P [(M+H)+], 591.2482; found 591.2487.    
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(naphthalen-1-yl)hexanoate (12h): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
55%. 1H NMR (300 MHz, CDCl3) δH ppm 1.37 (br. s, 9H, t-Bu), 1.45-1.75 (m, 4H, -CH2-), 
1.77-1.94 (m, 2H, -CH2-), 2.20-2.49 (m, 3H, -CH2-, -CH-), 2.98 (t, J = 7.1 Hz, 2H, -CH2-), 
4.86-5.09 (m, 4H, -CH2-Ph), 7.21-7.39 (m, 12H, Ar-H), 7.41-7.51 (m, 2H, Ar-H), 7.68 (d, J = 
8.4 Hz, 1H, Ar-H), 7.80-7.86 (m, 1H, Ar-H), 7.93-7.99 (m, 1H, Ar-H). 13C-NMR (75 MHz, 
CDCl3) δC ppm 27.8, 28.2, 30.1 (d, 1JC-P = 138.8 Hz), 30.5 (d, 2JC-P = 4.5 Hz), 33.1, 34.8 (d, 
3JC-P = 10.9 Hz), 40.3 (d, 3JC-P = 10.0 Hz), 66.9 (d, 2JC-P = 6.7 Hz), 7.2 (d, 2JC-P = 6.4 Hz), 80.5, 
123.9, 125.5, 125.6, 125.84, 126.0, 126.7, 128.1, 128.5, 128.7, 128.9, 131.9, 134.0, 135.3 (d, 
3JC-P = 6.4 Hz), 135.7 (d, 3JC-P = 6.1 Hz), 138.5, 171.7. 31P-NMR (121.5 MHz, CDCl3): δP ppm 
= 33.23. HRMS (ESI): calculated for C35H42O5P [(M+H)+], 573.2764; found 573.2761.    
Tert-butyl 3-((bis(benzyloxy)phosphoryl)methyl)-6-(naphthalen-2-yl)hexanoate (12i): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
49%. 1H NMR (300 MHz, CDCl3) δH ppm 1.39 (br. s, 9H, t-Bu), 1.44-1.96 (m, 6H, -CH2-), 
2.21-2.53 (m, 3H, -CH2-, -CH-), 2.71 (t, J = 7.2 Hz, 2H, -CH2-), 4.91-5.10 (m, 4H, -CH2-Ph), 
7.25-7.49 (m, 13H, Ar-H), 7.56 (s, 1H, Ar-H), 7.73-7.83 (m, 3H, Ar-H). 13C-NMR (75 MHz, 
CDCl3) δC ppm 28.0, 28.1, 29.9 (d, 1JC-P = 139.1 Hz), 30.3 (d, 2JC-P = 4.5 Hz), 34.2 (d, 3JC-P = 
10.5 Hz), 35.9, 40.2 (d, 3JC-P = 9.8 Hz), 66.9 (d, 2JC-P = 5.8 Hz), 67.00 (d, 2JC-P = 6.9 Hz), 80.3, 
125.0, 125.8, 126.3, 127.2, 127.3, 127.5, 127.8, 127.9, 128.3, 128.5, 131.9, 133.5, 136.4 (d, 
2JC-P = 6.2 Hz), 139.7, 171.6. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 32.13. HRMS (ESI): 
calculated for C35H42O5P [(M+H)+], 573.2764; found 573.2772.        
Tert-butyl 6-([1,1'-biphenyl]-4-yl)-3-((bis(benzyloxy)phosphoryl)methyl)hexanoate (12j): 
Prepared according to general procedure IV. Purification 2:1 hexane/ethyl acetate v/v; yield 
71%. 1H NMR (300 MHz, CDCl3) δH ppm 1.38 (br. s, 9H, t-Bu), 1.42-1.99 (m, 6H, -CH2-), 
2.20-2.63 (m, 5H, -CH2-, -CH-), 4.88-5.09 (m, 4H, -CH2-Ph), 7.17 (d, J = 8.2 Hz, 2H, Ar-H), 
7.25-7.60 (m, 17H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.0, 28.2, 29.9 (d, 1JC-P = 
138.5 Hz), 30.3 (d, 2JC-P = 3.9 Hz), 34.2 (d, 3JC-P = 10.9 Hz), 35.4, 40.2 (d, 3JC-P = 9.3 Hz), 
67.0 (d, 2JC-P = 6.6 Hz), 67.1 (d, 2JC-P = 6.4 Hz), 80.3, 126.9, 127.0, 127.9, 128.0, 128.3, 128.5, 
128.6, 128.7, 136.3 (d, 3JC-P = 6.1 Hz), 136.4 (d, 3JC-P = 6.1 Hz), 138.6, 141.0, 141.3, 171.6. 
31P-NMR (121.5 MHz, CDCl3): δP ppm = 31.83 HRMS (ESI): calculated for C37H44O5P 
[(M+H)+], 599.2921; found 599.2928.           
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(p-tolyl)pentyl)phosphonate 
(13a): Prepared according to general procedure V. Purification 3:1 hexane/acetone v/v; yield 
71%. 1H NMR (300 MHz, CDCl3) δH ppm 1.34-1.58 (m, 4H, -CH2-), 1.72-2.05 (m, 3H, -CH2-
, -CH-), 2.30 (s, 3H, Ph-CH3), 2.37-2.65 (m, 4H, -CH2-), 3.13 (s, 3H, N-CH3), 4.72 (s, 2H, 
NOCH2Ph), 4.86-5.06 (m, 4H, -POCH2Ph), 6.98 (d, J = 8.1 Hz, 2H, Ar-H), 7.05 (d, J = 8.1 
Hz, 2H, Ar-H), 7.28-7.36 (m, 15H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 19.2, 21.0, 
28.7, 29.6 (d, 1JC-P = 139.3 Hz), 29.6 (d, 2JC-P = 5.1 Hz), 33.5, 34.6 (d, 3JC-P = 10.2 Hz), 35.4, 
36.6 (d, 3JC-P = 9.2 Hz), 67.1 (d, 2JC-P = 6.3 Hz), 67.5 (d, 2JC-P = 6.1 Hz),, 76.1, 127.9, 127.9, 
128.2, 128.3, 128.5, 128.6, 128.9, 128.9, 129.3, 134.5, 135.0, 136.5 (m), 139.3, 173.8. 31P-
NMR (121.5 MHz, CDCl3): δP ppm = 33.55. HRMS (ESI): calculated for C36H43NO5P 
[(M+H)+], 600.2873; found 600.2903.    
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(m-tolyl)pentyl)phosphonate 
(13b): Prepared according to general procedure V. Purification 98:2 
dichloromethane/methanol v/v; yield 72%. 1H NMR (300 MHz, CDCl3) δH ppm 1.37-1 .59 
(m, 4H, -CH2-), 1.74-2.04 (m, 2H, -CH2-), 2.30 (s, 3H, Ph-CH3), 2.37-2.65 (m, 5H, -CH2-, -
CH-), 3.12 (s, 3H, N-CH3), 4.72 (s, 2H, NOCH2Ph), 4.89-5.05 (m, 4H, -POCH2Ph), 6.86-7.00 
(m, 3H, Ar-H), 7.13 (t, J = 7.4 Hz, 1H, Ar-H), 7.27-7.36 (m, 15H, Ar-H). 13C-NMR (75 MHz, 
CDCl3) δC ppm 21.3, 28.5, 28.6, 28.6 (d, 3JC-P = 8.8 Hz), 29.5 (d, 1JC-P = 138.8 Hz), 29.6 (d, 
2JC-P = 4.9 Hz), 34.6 (d, 3JC-P = 10.8 Hz), 35.7, 66.9 (m), 76.0, 125.3, 126.3, 127.8, 128.1, 
128.2, 128.5, 128.6, 128.8, 129.1, 129.2, 136.4 (m), 137.6, 142.3. 171.9. C 31P-NMR (121.5 
MHz, CDCl3): δP ppm = 33.54. HRMS (ESI): calculated for C36H43NO5P [(M+H)+], 
600.2873; found 600.2883. 
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(4-
methoxyphenyl)pentyl)phosphonate (13c): Prepared according to general procedure V. 
Purification 3:1 hexane/acetone v/v; yield 57%. 1H NMR (300 MHz, CDCl3) δH ppm 1.34-
1.59 (m, 4H, -CH2-), 1.73-2.04 (m, 2H, -CH2-), 2.26-2.65 (m, 5H, -CH2-, -CH-), 3.13 (s, 3H, 
N-CH3), 3.75 (s, 3H, PhOCH3),  4.72 (s, 2H, -NOCH2Ph), 4.88-5.07 (m, 4H, -POCH2Ph), 
6.78 (d, J = 9.6 Hz, 2H, Ar-H), 7.00 (d, J = 9.6 Hz, 2H, Ar-H), 7.27-7.39 (m, 15H, Ar-H). 
13C-NMR (75 MHz, CDCl3) δC ppm 29.1, 29.9 (d, 2JC-P = 4.3 Hz), 30.0, 30.1 (d, 1JC-P = 136.9 
Hz), 34.8 (d, 3JC-P = 9.8 Hz), 35.1, 36.9 (d, 3JC-P = 9.2 Hz), 55.5, 67.2 (d, 2JC-P = 6.7 Hz), 67.3 
(d, 2JC-P = 6.1 Hz), 76.3, 113.9, 128.2, 128.5, 128.8, 128.9, 129.1, 129.5, 129.6, 134.7, 134.8 
(d, 3JC-P = 5.5 Hz), 136.7, 157.9, 173.5. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 32.35. 
HRMS (ESI): calculated for C36H43NO6P [(M+H)+], 616.2823; found 616.2830.  
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(3-
methoxyphenyl)pentyl)phosphonate (13d): Prepared according to general procedure V. 
Purification 5:1 dichloromethane/ethyl acetate v/v; yield 51%. 1H NMR (300 MHz, CDCl3) 
δH ppm 1.35-1.61 (m, 4H, -CH2-), 1.72-2.07 (m, 2H, -CH2-), 2.27-2.67 (m, 5H, -CH2-, -CH-), 
3.12 (s, 3H, N-CH3), 3.75 (s, 3H, PhOCH3),  4.72 (s, 2H, -NOCH2Ph), 4.87-5.07 (m, 4H, -
POCH2Ph), 6.64-6.74 (m, 3H, Ar-H), 7.16 (t, J = 7.9 Hz, 1H, Ar-H), 7.26-7.37 (m, 15H, Ar-
H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.4, 29.5 (d, 2JC-P = 4.5 Hz), 29.6 (d, 1JC-P = 138.4 
Hz), 29.7, 34.5 (d, 3JC-P = 10.3 Hz), 35.8, 36.6 (d, 3JC-P = 9.0 Hz), 55.0, 66.8 (d, 2JC-P = 6.7 
Hz), 66.9 (d, 2JC-P = 6.6 Hz), 76.0, 110.9, 114.0, 120.7, 127.8, 128.2, 128.4, 128.6, 128.8, 
129.1, 129.2, 134.5, 136.4 (d, 3JC-P = 6.1 Hz), 136.4 (d, 3JC-P = 6.1 Hz), 144.0, 159.5, 173.7. 
31P-NMR (121.5 MHz, CDCl3): δP ppm = 32.31. HRMS (ESI): calculated for C36H43NO6P 
[(M+H)+], 616.2823; found 616.2831.  
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(4-
fluorophenyl)pentyl)phosphonate (13e): Prepared according to general procedure V. 
Purification 3:1 hexane/acetone v/v; yield 71%. 1H NMR (300 MHz, CDCl3) δH ppm 1.36-
1.56 (m, 4H, -CH2-), 1.71-2.02 (m, 2H, -CH2-), 2.23-2.50 (m, 5H, -CH2-, -CH-), 3.13 (s, 3H, 
N-CH3), 4.73 (s, 2H, -NOCH2Ph), 4.87-5.09 (m, 4H, -POCH2Ph), 6.85-7.06 (m, 4H, Ar-H), 
7.27-7.39 (m, 15H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.6, 29.6 (d, 2JC-P = 4.3 Hz), 
29.7 (d, 3JC-P = 10.0 Hz), 34.4 (d, 3JC-P = 10.0 Hz), 34.9, 36.7 (d, 3JC-P = 10.0 Hz), 37.0, 66.9 
(d, 2JC-P = 6.6 Hz), 67.0 (d, 2JC-P = 6.3 Hz), 76.1, 114.9 (d, 2JC-F = 21.8 Hz), 127.8 (d, 3JC-F = 
9.8 Hz), 127.9, 128.3, 128.6, 128.9, 129.2, 129.5, 134.5, 136. 4 (d, 3JC-P = 6.7 Hz), 137.9 (d, 
4JC-F = 4.2 Hz), 161.2 (d, 1JC-F = 242.42 Hz), 173.4. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 
32.11. HRMS (ESI): calculated for C35H40FNO5P [(M+H)+], 604.2623; found 604.2657.  
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(3-
fluorophenyl)pentyl)phosphonate (13f): Prepared according to general procedure V. 
Purification 3:1 hexane/acetone v/v; yield 69%. 1H NMR (300 MHz, CDCl3) δH ppm 1.32-
1.58 (m, 4H, -CH2-), 1.69-2.03 (m, 2H, -CH2-), 2.25-2.53 (m, 5H, -CH2-, -CH-), 3.13 (s, 3H, 
N-CH3), 4.73 (s, 2H, -NOCH2Ph), 4.86-5.09 (m, 4H, -POCH2Ph), 6.73-7.92 (m, 3H, Ar-H), 
7.14-7.38 (m, 16H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.2, 29.6 (d, 2JC-P = 4.1 Hz), 
29.7 (d, 1JC-P = 137.6 Hz), 31.6, 34.4 (d, 3JC-P = 9.83 Hz), 35.5, 36.7 (d, 3JC-P = 9.1 Hz), 66.9 
(d, 2JC-P = 6.7 Hz), 67.0 (d, 2JC-P = 6.0 Hz), 76.1, 112.5 (d, 2JC-F = 22.0 Hz), 115.1 (d, 2JC-F = 
22.0 Hz), 124.0 (d, 4JC-F = 3.1 Hz), 127.9, 128.3, 128.5, 128.6, 128.9, 129.3, 129.5 (d, 3JC-F = 
8.6 Hz), 134.5, 136.4 (d, 3JC-P = 6.1 Hz), 144.9 (d, 3JC-F = 7.7 Hz), 162.8 (d, 1JC-F = 244.7 Hz), 
173.25. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.43. HRMS (ESI): calculated for 
C35H40FNO5P [(M+H)+], 604.2623; found 604.2656.  
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(4-
(trifluoromethyl)phenyl)pentyl)phosphonate (13g): Prepared according to general 
procedure V. Purification 3:1 hexane/acetone v/v; yield 55%. 1H NMR (300 MHz, CDCl3) δH 
ppm 1.34-1.59 (m, 4H, -CH2-), 1.70-2.05 (m, 2H, -CH2-), 2.25-2.64 (m, 5H, -CH2-, -CH-), 
3.12 (s, 3H, N-CH3), 4.72 (s, 2H, -NOCH2Ph), 4.87-5.08 (m, 4H, -POCH2Ph), 7.17 (d, J = 8.2 
Hz, 2H, Ar-H), 7.32 (m, 15H, Ar-H), 7.48 (d, J = 8.2 Hz, 2H, Ar-H). 13C-NMR (75 MHz, 
CDCl3) δC ppm 28.2, 29.5 (d, 2JC-P = 3.6 Hz), 29.7 (d, 1JC-P = 138.2 Hz), 32.8, 34.4 (d, 3JC-P = 
10.1 Hz), 35.5, 36.7 (d, 3JC-P = 9.5 Hz), 66.9 (d, 2JC-P = 6.4 Hz), 67.0 (d, 2JC-P = 6.6 Hz), 76.1, 
124.5 (quart., 1JC-F = 272.7 Hz), 125.1 (quart., 4JC-F = 3.8 Hz), 127.9, 128.2 (quart., 2JC-F = 22.1 
Hz), 128.3, 128.5, 128.6, 128.9, 129.2, 134.5, 136.4 (d, 3JC-P = 6.3 Hz), 146.4, 173.8. 31P-
NMR (121.5 MHz, CDCl3): δP ppm = 33.43. HRMS (ESI): calculated for C36H40F3NO5P 
[(M+H)+], 654.2591; found 654.2601.   
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(naphthalen-1-
yl)pentyl)phosphonate (13h): Prepared according to general procedure V. Purification 98:2 
dichloromethane/methanol v/v; yield 44%. 1H NMR (300 MHz, CDCl3) δH ppm 1.50-2.04 (m, 
6H, -CH2-), 2.29-2.64 (m, 3H, -CH2-, -CH-), 2.90-3.00 (m, 2H, -CH2-), 3.12 (s, 3H, N-CH3), 
4.68 (s, 2H, -NOCH2Ph), 4.88-5.05 (m, 4H, -POCH2Ph), 7.19-7.40 (m, 17H, Ar-H), 7.43-7.50 
(m, 2H, Ar-H), 7.66-7.72 (m, 1H, Ar-H), 7.80-7.86 (m, 1H, Ar-H), 7.93-7.99 (m, 1H, Ar-H). 
13C-NMR (75 MHz, CDCl3) δC ppm 28.1, 29.9 (d, 1JC-P = 138.4 Hz), 29.9 (d, 2JC-P = 4.9 Hz), 
33.2, 35.2 (d, 3JC-P = 9.8 Hz), 36.9 (d, 3JC-P = 8.5 Hz), 67.2 (d, 2JC-P = 6.7 Hz), 67.3 (d, 2JC-P = 
6.7 Hz), 76.3, 124.1, 125.6, 125.8, 125.9, 126.1, 126.7, 128.2, 128.5, 128.8, 128.9, 129.0, 
129.1, 129.5, 132.0, 134.1, 134.8, 136.7 (d, 3JC-P = 6.4 Hz), 136.7 (d, 1JC-P = 6.1 Hz), 138.8, 
168.0. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.49. HRMS (ESI): calculated for 
C39H43NO5P [(M+H)+], 636.2873; found 636.2880.   
Dibenzyl (2-(2-((benzyloxy)(methyl)amino)-2-oxoethyl)-5-(naphthalen-2-
yl)pentyl)phosphonate (13i): Prepared according to general procedure V. Purification 3:1 
hexane/acetone v/v; yield 78%. 1H NMR (300 MHz, CDCl3) δH ppm 1.37-2.02 (m, 6H, -CH2-
), 2.26-2.75 (m, 5H, -CH-, -CH2-), 3.11 (s, 1H, N-CH3), 4.71 (s, 2H, -NOCH2Ph), 4.85-5.08 
(m, 4H, -POCH2Ph), 7.21-7.34 (m, 16H, Ar-H), 7.36-7.47 (m, 2H, Ar-H), 7.53 (s, 1H, Ar-H), 
7.70-7.81 (m, 3H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.7, 29.9 (d, 2JC-P = 3.9 Hz), 
30.0 (d, 1JC-P = 138.8 Hz), 32.9, 34.8 (d, 3JC-P = 10.4 Hz), 36.2, 36.9 (d, 3JC-P = 9.1 Hz), 67.2 
(d, 2JC-P = 6.6 Hz), 67.3 (d, 2JC-P = 6.0 Hz), 76.3, 125.3, 126.0, 126.6, 127.5, 127.6, 127.8, 
128.0, 128.2, 128.5, 128.8, 128.9, 129.1, 129.5, 132.2, 133.8, 134.8, 136.7 (d, 2JC-P = 6.6 Hz), 
136.8 (d, 2JC-P = 6.2 Hz), 140.1, 170.4. 31P-NMR (121.5 MHz, CDCl3): δP ppm = 33.49. 
HRMS (ESI): calculated for C39H43NO5P [(M+H)+], 636.2873; found 636.2880.   
Dibenzyl (5-([1,1'-biphenyl]-4-yl)-2-(2-((benzyloxy)(methyl)amino)-2-
oxoethyl)pentyl)phosphonate (13j): Prepared according to general procedure V. Purification 
97:3 dichloromethane/ethyl acetate v/v; yield 68%. 1H NMR (300 MHz, CDCl3) δH ppm 1.38-
1.64 (m, 4H, -CH2-), 1.75-2.04 (m, 2H, -CH2-), 2.28-2.66 (m, 5H, -CH2-, -CH-), 3.13 (s, 3H, 
N-CH3), 4.72 (s, 2H, NOCH2Ph), 4.89-5.07 (m, 4H, -POCH2Ph), 7.11-7.19 (m, 3H, Ar-H), 
7.25-7.60 (m, 21H, Ar-H). 13C-NMR (75 MHz, CDCl3) δC ppm 28.5, 29.6 (d, 2JC-P = 4.7 Hz), 
30.3, 29.6 (d, 1JC-P = 138.2 Hz), 34.5 (d, 3JC-P = 10.2 Hz), 35.4, 36.6 (d, 3JC-P = 10.2 Hz), 66.9 
(d, 2JC-P = 6.1 Hz), 70.0 (d, 2JC-P = 6.6 Hz), 76.0, 126.9, 127.9, 128.2, 128.5, 128.6, 128.7, 
128.8, 128.9, 129.2, 134.5, 136.4 (d, 3JC-P = 6.4 Hz), 138.5, 141.0, 141.5,172.6. 31P-NMR 
(121.5 MHz, CDCl3): δP ppm = 32.33. HRMS (ESI): calculated for C41H45NO5P [(M+H)+], 
662.3030; found 662.3039.       
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(p-
tolyl)pentyl)phosphonate (6a): White powder. Prepared from compound 13a (150 mg, 0.25 
mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.29-1.78 (m, 
6H, -CH2-), 1.94-2.41 (m, 4H, -CH-, Ph-CH3), 2.45-2.70 (m, 4H, -CH2-), 3.01 (s, 5/6 of N-
CH3), 3.23 (s, 1/6 of N-CH3), 6.89-7.23 (m, 4H, Ar-H). 13C-NMR (75 MHz, D2O) δC ppm 
20.0, 27.6, 30.5 (d, 2JC-P = 4.3 Hz), 31.6 (d, 1JC-P = 130.7 Hz), 34.1 (d, 3JC-P = 12.7 Hz), 34.5, 
37.0, 39.2 (d, 1JC-P = 7.1 Hz), 128.4, 128.9, 135.4, 139.8, 177.8. 31P-NMR (121.5 MHz, D2O): 
δP ppm 25.97. HRMS (ESI): calculated for C15H23NO5P [(M-H)-], 328.1319; found 328.1320. 
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(m-
tolyl)pentyl)phosphonate (6b): White powder. Prepared from compound 13b (150 mg, 0.25 
mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.22-1.69 (m, 
6H, -CH2-), 1.99-2.23 (m, 1H, -CH-), 2.28 (s, 3H, Ph-CH3), 2.49-2.68 (m, 4H, -CH2-), 3.18 (s, 
5/6 of N-CH3), 3.35 (s, 1/6 of N-CH3), 7.02-7.15 (m, 3H, Ar-H), 7.23 (app. t, J = 7.4 Hz, 1H, 
Ar-H). 13C-NMR (75 MHz, D2O) δC ppm 20.5, 28.4, 32.2 (d, 2JC-P = 4.1 Hz), 33.4 (d, 1JC-P = 
130.7 Hz), 35.3, 35.4 (d, 3JC-P = 9.8 Hz), 36.2, 36.3 (d, 3JC-P = 5.9 Hz), 125.8, 126.5, 128.7, 
129.4, 138.7, 143.8, 174.4. 31P-NMR (121.5 MHz, D2O): rotamers at δP ppm 22.14 and 22.25. 
HRMS (ESI): calculated for C15H23NO5P [(M-H)-], 328.1319; found 328.1318. 
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(4-
methoxyphenyl)pentyl)phosphonate (6c): White powder. Prepared from compound 13c 
(125 mg, 0.20 mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 
1.23-1.66 (m, 6H, -CH2-), 2.01-2.26 (m, 1H, -CH-), 2.47-2.67 (m, 4H, -CH2-), 3.17 (s, 5/6 of 
N-CH3), 3.34 (s, 1/6 of N-CH3), 3.78 (s, 3H, PhOCH3), 6.91 (m, 2H, Ar-H), 7.21 (m, 2H, Ar-
H). 13C-NMR (75 MHz, D2O) δC ppm 28.3, 32.0 (d, 2JC-P = 4.0 Hz), 33.3 (d, 1JC-P = 129.9 Hz), 
34.4, 35.1 (d, 3JC-P = 10.7 Hz), 36.1, 36.4 (d, 3JC-P = 6.2 Hz), 55.6, 114.1, 129.9, 136.2, 156.9, 
175.0. 31P-NMR (121.5 MHz, D2O): δP ppm = 22.48. HRMS (ESI): calculated for 
C15H23NO6P [(M-H)-], 344.1268; found 344.1269. 
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(3-
methoxyphenyl)pentyl)phosphonate (6d): White powder. Prepared from compound 13d 
(150 mg, 0.24 mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 
1.24-1.69 (m, 6H, -CH2-), 2.02-2.26 (m, 1H, -CH-), 2.51-2.66 (m, 4H, -CH2-), 3.17 (s, 5/6 of 
N-CH3), 3.34 (s, 1/6 of N-CH3), 3.79 (s, 3H, Ph-OCH3), 6.77-6.93 (m, 3H, Ar-H), 7.26 (app. 
t, J = 7.9 Hz, 1H, Ar-H). ). 13C-NMR (75 MHz, D2O) δC ppm 28.0, 31.8 (d, 2JC-P = 4.1 Hz), 
33.1 (d, 1JC-P = 130.2 Hz), 35.1 (d, 3JC-P = 10.6 Hz), 35.4, 36.1, 36.5 (d, 3JC-P = 7.3 Hz), 55.4, 
111.5, 114.2, 121.7, 129.8, 145.5, 159.0, 175.2. 31P-NMR (121.5 MHz, D2O): δP ppm = 21.72. 
HRMS (ESI): calculated for C15H23NO6P [(M-H)-], 344.1268; found 344.1269. 
Sodium hydrogen (5-(4-fluorophenyl)-2-(2-(hydroxy(methyl)amino)-2-
oxoethyl)pentyl)phosphonate (6e): White powder. Prepared from compound 13e (100 mg, 
0.17 mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.14-1.68 
(m, 6H, -CH2-), 1.92-2.20 (m, 1H, -CH-), 2.42-2.66 (m, 4H, P-CH2-, CH2-CON-), 3.14 (s, 5/6 
of N-CH3), 3.27 (s, 1/6 of N-CH3), 6.97-7.09 (m, 2H, Ar-H), 7.20-7.33 (m, 2H, Ar-H). 13C-
NMR (75 MHz, D2O) δC ppm 28.0, 31.4 (d, 2JC-P = 4.5 Hz), 33.9 (d, 1JC-P = 139.3 Hz), 34.6 
(d, 3JC-P = 8.1 Hz), 34.7, 36.3 (d, 3JC-P = 8.3 Hz), 37.1, 114.7 (d, 2JC-F = 21.2 Hz), 129.9 (d, 3JC-
F = 8.3 Hz), 139.2 (d, 4JC-F = 3.7 Hz), 160.7 (d, 1JC-F = 239.1 Hz), 169.0. 31P-NMR (121.5 
MHz, D2O): rotamers at δP ppm 21.40, 21.50. HRMS (ESI): calculated for C14H21FNO5P [(M-
H)-], 332.1069; found 332.1088. 
Sodium hydrogen (5-(3-fluorophenyl)-2-(2-(hydroxy(methyl)amino)-2-
oxoethyl)pentyl)phosphonate (6f): White powder. Prepared from compound 13f (130 mg, 
0.22 mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.23-1.68 
(m, 6H, -CH2-), 2.02-2.23 (m, 1H, -CH-), 2.50-2.69 (m, 4H, -CH2-), 3.17 (s, 5/6 of N-CH3), 
3.35 (s, 1/6 of N-CH3), 6.88-7.10 (m, 3H, Ar-H), 7.25-7.34 (m,1H, Ar-H). 13C-NMR (75 
MHz, D2O) δC ppm 27.9, 31.9 (d, 2JC-P = 4.1 Hz), 33.1 (d, 1JC-P = 129.1 Hz), 35.0 (d, 3JC-P = 
8.2 Hz), 35.1, 36.1, 36.4 (d, 3JC-P = 7.0 Hz), 112.5 (d, 2JC-F = 23.32 Hz), 115.3 (d, 2JC-F = 21.9 
Hz), 124.6 (d, 4JC-F = 2.7 Hz), 130.1 (d, 3JC-F = 8.7 Hz), 146.2 (d, 3JC-F = 8.7 Hz), 162.9 (d, 1JC-
F = 247.1 Hz), 175.0. 31P-NMR (121.5 MHz, D2O): δP ppm = 22.75. HRMS (ESI): calculated 
for C14H20FNO5P [(M-H)-], 332.1069; found 332.1067. 
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(4-
(trifluoromethyl)phenyl)pentyl)phosphonate (6g): White powder. Prepared from 
compound 13g (150 mg, 0.25 mmol) according to general procedure VI. 1H NMR (300 MHz, 
D2O) δH ppm 1.27-1.71 (m, 6H, -CH2-), 2.00-2.26 (m, 1H, -CH-), 2.50-2.61 (m, 2H, -CH2-), 
2.66 (t, J = 7.4 Hz, 2H, -CH2-), 3.16 (s, 5/6 of N-CH3), 3.34 (s, 1/6 of N-CH3), 3.79 7.40 (d, J 
= 7.9 Hz, 2H, Ar-H), 7.61 (d, J = 7.9 Hz, 2H, Ar-H). 13C-NMR (75 MHz, D2O) δC ppm 27.5, 
29.5, 31.5 (d, 2JC-P = 4.1 Hz), 32.8 (d, 1JC-P = 130.7 Hz), 34.5 (d, 3JC-P = 11.0 Hz), 34.9, 35.8, 
36.3 (d, 3JC-P = 6.8 Hz), 124.4 (quart., 1JC-F = 270.5 Hz), 125.0 (quart., 3JC-F = 4.1 Hz), 128.9 
(app. s), 147.6, 174.9. 31P-NMR (121.5 MHz, D2O): δP ppm = 21.49. HRMS (ESI): calculated 
for C15H20F3NO5P [(M-H)-], 382.1037; found 382.1039. 
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(naphthalen-1-
yl)pentyl)phosphonate (6h): White powder. Prepared from compound 13h (150 mg, 0.24 
mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.38-1.84 (m, 
6H, -CH2-), 2.02-2.27 (m, 1H, -CH-), 2.46-2.65 (m, 2H, -CH2-), 3.07 (t, J = 7.6 Hz, 2H, -CH2-
), 3.13 (s, 5/6 of N-CH3), 3.24 (s, 1/6 of N-CH3), 7.39-7.62 (m, 4H, Ar-H), 7.78 (dd, J = 2.4 
Hz, 7.4 Hz, 1H, Ar-H), 7.92 (dd, J = 2.4 Hz, 8.1 Hz, 1H, Ar-H), 8.18 (d, J = 8.1 Hz, 1H, Ar-
H). 13C-NMR (75 MHz, D2O) δC ppm 27.8, 32.1 (d, 2JC-P = 4.5 Hz), 32.7, 33.8 (d, 1JC-P = 
129.3 Hz), 34.5, 35.7 (d, 3JC-P = 10.8 Hz), 36.4 (d, 3JC-P = 7.6 Hz), 36.6, 124.4, 126.1, 126.2, 
126.3, 126.4, 128.8, 131.6, 133.7, 139.7, 172.7. 31P-NMR (121.5 MHz, D2O): rotamers at δP 
ppm 21.94, 22.18. HRMS (ESI): calculated for C18H23NO5P [(M-H)-], 364.1319; found 
364.1315. 
Sodium hydrogen (2-(2-(hydroxy(methyl)amino)-2-oxoethyl)-5-(naphthalen-2-
yl)pentyl)phosphonate (6i): White powder. Prepared from compound 13i (150 mg, 0.24 
mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.23-1.80 (m, 
6H, -CH2-), 2.01-2.29 (m, 1H, -CH-), 2.46-2.65 (m, 2H, -CH2-), 2.78 (t, J = 7.8 Hz, 2H, -CH2-
), 3.12 (s, 5/6 of N-CH3), 3.30 (s, 1/6 of N-CH3), 7.44-7.55 (m, 3H, Ar-H), 7.77 (s, 1H, Ar-H), 
7.84-7.92 (m, 3H, Ar-H). 13C-NMR (75 MHz, D2O) δC ppm 29.8, 31.8 (d, 2JC-P = 3.7 Hz), 
34.1 (d, 1JC-P = 130.8 Hz), 35.0 (d, 3JC-P = 10.9 Hz), 35.8, 36.5 (d, 3JC-P = 8.0 Hz), 37.3, 125.5, 
126.3, 126.4, 127.5, 127.7, 127.9, 128.1, 131.7, 133.5, 141.6, 169.7. 31P-NMR (121.5 MHz, 
D2O): δP ppm = 22.48. HRMS (ESI): calculated for C18H23NO5P [(M-H)-], 364.1319; found 
364.1315. 
Sodium hydrogen (5-([1,1'-biphenyl]-4-yl)-2-(2-(hydroxy(methyl)amino)-2-
oxoethyl)pentyl)phosphonate (6j): White powder. Prepared from compound 13j (200 mg, 
0.30 mmol) according to general procedure VI. 1H NMR (300 MHz, D2O) δH ppm 1.23-1.73 
(m, 6H, -CH2-), 1.98-2.24 (m, 1H, -CH-), 2.42-2.70 (m, 4H, -CH2-), 3.14 (s, 5/6 of N-CH3), 
3.30 (s, 1/6 of N-CH3), 7.35-7.53 (m, 5H, Ar-H), 7.58-7.71 (m, 4H, Ar-H). 13C-NMR (75 
MHz, D2O) δC ppm 27.9, 31.5 (d, 2JC-P = 4.1 Hz), 33.0 (d, 1JC-P = 130.1 Hz), 34.5 (d, 2JC-P = 
10.1 Hz), 35.0, 36.3 (d, 3JC-P = 8.38 Hz), 37.1, 126.7, 126.8, 127.4, 129.0, 129.3, 137.8, 140.4, 
143.1, 169.2. 31P-NMR (121.5 MHz, D2O): rotamers at δP ppm 21.37, 21.54. HRMS (ESI): 
calculated for C20H25NO5P [(M-H)-], 390.1476; found 390.1479. 
 
X-ray crystallography 
Protein was produced and assayed as described earlier.[23] The water-soluble ligands (6a, 6b, 
6c, 6d, 6f, 6g, 6h) were incubated (final concentration, 1 mM) with the protein solution (0.3 
mM in 20 mM Tris-HCl, pH 7.8, 200-300 mM NaCl, 5% (v/v) glycerol, 2 mM dithiothreitol 
and 1 mM MnCl2) for 10-15 min at 20 °C before the co-crystallization experiments were set 
up in 2-well MRC plates (Molecular Dimensions, UK) with a Mosquito robot (TTP Labtech, 
UK). Reservoir solutions consisted of 40 L, and the sitting droplets contained equal volumes 
(100 nL each) of the protein–ligand mixture and reservoir solution. Previous screening[23] had 
shown the Morpheus screen[34] was highly effective for this protein, and crystals (0.1 x 0.1 x 
0.1 mm) appeared in 1-3 days at 20 °C in multiple conditions (Table S1). Crystals were 
harvested without further cryoprotection, and plunged into liquid nitrogen for transport to the 
relevant synchrotron beamline. 
Diffraction data were collected at 100 K at the European Synchrotron Radiation Facility 
(ESRF, Grenoble, France) or at Diamond, Oxford, England (see Table S2). All crystals had 
the symmetry of the triclinic space group P1, and could be classified into the same one of the 
two related groups of P1 cells discussed earlier.[23] Diffraction images were processed and 
scaled with XDS[35] and SCALA[36] respectively, using the CCP4 package.[37] Rigid-body 
refinement was used for initial placement of the structures, to maintain a similar position 
relative to that seen earlier. Structures were then subjected to alternating rounds of reciprocal 
space refinement with REFMAC5[38] and manual rebuilding with O.[39] Solvent was added 
using the water tools in O. The ligands and respective stereochemical restraints were built and 
generated with the qds tools in O. Refinement restraints were then generated from the fitted 
models by REFMAC5, and manually edited as needed. Hydroxamate groups were restrained 
to planarity, and metal-coordination target distances were taken from Harding (2006).[40] 
Complete data collection and refinement statistics are included in Table S2. 
Briefly, the structures of the seven new -substituted enzyme-inhibitor complexes (6a, 6b, 6c, 
6d, 6f, 6g, 6h) were solved at resolutions of 1.55, 1.8, 1.7, 1.7, 1.7, 1.6 and 1.4 Å, 
respectively, and refined to crystallographic R-factors of 18.6, 17.7, 18.2, 16.9, 18.2, 18.0 and 
18.7% (R-frees are 20.5, 20.4, 21.1, 20.3, 20.8 and 20.7%, respectively). Each complex has a 
dimer in the asymmetric unit, with a manganese ion and ligand in each active site. Although 
the new compounds were synthesized as racemic mixtures, the high resolution of the study 
(e.g. Figure 4A4a) allowed us to define the respective enantiomer of each ligand. The overall 
electron density is of high quality, and complete models of the enzyme are deposited for 
residues 77-486 in each chain. Density for residues in the active-site flap is discussed in the 
main text, and described further in Table S3. Structural comparisons were made with the lsq 
commands in O with close-pair C cut-offs (1.0 Å C - C separations).[41] Figures were 
created in O, using secondary structure assignments from the yasspa algorithm, and rendered 
in Molray.[42] Structures of the various complexes were deposited at the Protein Data Bank, as 
follows: 6a (5JMW), 6b (5JO0), 6c (5JBI), 6d (5JC1), 6f (5JMP), 6g (5JNL) and 6h (5JAZ). 
Electron density for each entry is available at the Uppsala Electron Density Server.[43] 
 
Supporting Information 
Additional experimental details are presented, including comparisons of pIC50 for EcDxr and 
PfDxr, comparisons of pIC50 with crystallographic temperature factors and fit to electron 
density, crystallization conditions used in the reported X-ray structures, statistics for data 
collection and refinement, and summary of electron density in residues of the flap. 
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